- Tilray Brands’ (TLRY) medical cannabis division, Tilray Medical, has expanded its medical cannabis offerings in the United Kingdom
- Tilray Medical now offers the broadest portfolio of cannabis flower in the UK market
- In the UK, patients may obtain prescriptions for medical cannabis through their specialist doctor
- Tilray Medical provides patients with safe and reliable access to high-quality medical cannabis
- Tilray Stock (TSX:TLRY) was down 3.81 per cent, trading at C$4.29 per share at 12:00 pm ET
Tilray Brands’ (TLRY) medical cannabis division, Tilray Medical, has expanded its medical cannabis offerings in the United Kingdom.
Tilray Medical now offers the broadest portfolio of cannabis flower in the UK market. It includes a differentiated range of high THC products, cultivated at its EU-GMP-certified facility in Portugal.
Denise Faltischek, Chief Strategy Officer and Head of International Business of Tilray commented on the news.
“The demand for medical cannabis in the UK is growing rapidly. We are incredibly proud to provide patients in the UK with high-quality, consistent medical cannabis products they can rely on and are accessible to them.”
Tilray Medical’s market leading portfolio of cannabis flowers has THC potencies that span from 10 to 25 per cent and offer a range of different ratios.
The company’s cultivars have a unique profile of cannabinoids and terpenes. Each is selected to ensure patients receive the highest product quality and consistency in the supply of their medicinal cannabis products.
Tilray Medical hopes to expand the range of treatment options available to patients and ensure prescribers and patients are provided with a safe and reliable choice as they embark on their medical cannabis journey. In the UK, patients may obtain prescriptions for medical cannabis through their specialist doctor.
Tilray Medical provides patients with safe and reliable access to high-quality medical cannabis. It is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.
